O CNS - Campus Neurológico nasce com o objetivo de facultar a doentes, familiares e cuidadores, num mesmo espaço físico, uma abordagem multidisciplinar, especializada em doença de Parkinson e outras doenças do movimento, doença de Alzheimer e outras demências, Acidentes Vasculares Cerebrais (AVC) e outras doenças neurológicas.
Adicionalmente, através das unidades CNS Science e CNS Academy, o CNS pretende conciliar uma atividade clínica de excelência com a condução de projetos de investigação de qualidade e a formação de profissionais de saúde e do público em geral.
O CNS tem como missão melhorar a qualidade de vida e autonomia dos seus doentes, utilizando para tal uma abordagem multidisciplinar especializada, realizada por profissionais de saúde de competência reconhecida, em colaboração com os familiares e cuidadores. Tem ainda o propósito de formar os doentes e famílias, tornando-os parte integrante do processo de decisão clínica.
Posicionar-se como um espaço único na área das doenças neurológicas em Portugal e na Europa, associando um centro de cuidados multidisciplinares especializados de excelência, com atividade académica e de formação.
Como forma de materializar a sua missão e visão, os colaboradores do CNS respeitam e transmitem, em todas as atividades realizadas, os seguintes valores:
Qualidade dos cuidados de saúde
Humanização dos cuidados
Valorização e respeito pela autonomia do doente, dignidade humana e diversidade cultural
Colaboração com familiares, cuidadores e outros profissionais de saúde
Integração e complementaridade das valências e serviços prestados na perspectiva do benefício dos doentes e familiares
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205
The primary objective is to evaluate the safety and tolerability of aducanumab over 100 weeks of treatment after a wash-out period imposed by discontinuation of feeder studies in participants who had previously received aducanumab (i.e. previously treated participants) or who had previously received placebo (i.e. treatment-naïve participants).
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
This study will be conducted to evaluate the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)
This is a Phase 1/2, multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of DNL593 in two parts followed by an optional open-label extension (OLE) period. Part A will evaluate the safety, tolerability, PK, and PD of single doses of DNL593 in healthy male and healthy female participants of nonchildbearing potential. Part B will evaluate the safety, tolerability, PK, and PD of multiple doses of DNL593 in participants with frontotemporal dementia (FTD) over 25 weeks. Part B will be followed by Part C, an optional 18-month OLE period available for all participants who complete Part B.
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
This is a multi-center, randomized, double-blind, double-dummy, active controlled clinical Study. Following a screening period, eligible subjects will be enrolled to an open-label oral IR-LD/CD adjustment period; then an open-label ND0612 conversion period; then after optimization periods subjects will be randomized to receive either ND0612 or its matching Placebo with IR-LD/CD. Subjects can continue to an optional open-label extension period.
The Feasibility and Efficacy of an Immersive Virtual Reality Software in Parkinson's Disease Patients
The Dolphin 2.0 is a platform that runs an immersive virtual reality software, based on an oceanic environment, where players control simulated creatures (dolphin, orca, axolotl). Video games lead to high levels of motivation and arousal, provide immediate feedback and playback, provide explicit reward and implicit success, and titrate difficulty levels. This encourages the practice of exercise, being an important complement to physiotherapy sessions. The main goal of this study is to evaluate the feasibility, safety and efficacy of an immersive virtual reality software (Dolphin, 2.0) in Parkinson's disease symptomatic control, in a two-arm, randomized, single-blind (blind rater for primary and secondary outcomes), delayed-start feasibility and efficacy trial.
Feasibility of the AHA Exergame System in Parkinson's Disease Patients
Background: Parkinson's disease (PD) remains a progressive disease associated with a high level of disability. Due to the physical and cognitive impairments, fatigue and apathy, patients frequently experience a decrease in their daily physical activity. Exercise programs have been recommended for symptomatic control, however, its implementation is still challenging in terms of acceptability and adherence. Exergames (i.e. exercise based on video games) have been proposed as a potential, home-based rehabilitation tool to improve PD patients motor skills and to promote a more active lifestyle.
Epidemiological Study in FRONtoTemporal Dementia
An international, multicenter, epidemiological observational study aims to investigate the prevalence of genetic etiologies in patients diagnosed with FTD or clinically suspected for FTD.
Study of Evobrutinib in Participants With RMS (evolutionRMS 2)
The study is to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Teriflunomide (Aubagio®), administered orally once daily in participants with Relapsing Multiple Sclerosis (RMS). Participants who complete the double-blind treatment period (DBTP) and double-blind extension period (DBEP) prior to approval of a separate long-term follow-up study in their country will get an option for evobrutinib treatment continuation through a 96-week open-label extension (OLE) period.
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
This study will evaluate the efficacy and safety of ocrelizumab ( Ocrevus®) compared with placebo in participants with primary progressive multiple sclerosis (PPMS), including participants later in their disease course. This study focuses on upper limit disability progression. This study will consist of the following phases: screening, double-blind treatment, follow-up 1 (FU1), an optional open-label extension (OLE), follow-up 2 (FU2), and B-cell monitoring (BCM).
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease.
This study will evaluate the safety, biomarkers, and efficacy of tominersen compared with placebo in participants with prodromal and early manifest Huntington's Disease.
eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.
This is a randomized, parallel group, multicentre, multinational, prospective, open-label exploratory study in Parkinson's disease (PD) patients to evaluate the add-on efficacy of opicapone 50 mg or an extra dose of levodopa (L-DOPA) 100 mg as first strategy for the treatment of wearing-off.
A Study of TAK-341 in Treatment of Multiple System Atrophy
The main aim is to see how TAK-341 works after 52 weeks in participants with multiple system atrophy as measured by the Unified Multiple System Atrophy Rating Scale Part I (UMSARS). The study will enroll approximately 138 patients. Participants will receive a total of 13 intravenous infusions every 4 weeks approximately, these may be either of TAK-341 or placebo, after each infusion some blood samplings will be taken and other assessments completed. This trial will be conducted in North America, Europe and Asia.
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
This study will evaluate the efficacy and safety of ocrelizumab ( Ocrevus®) compared with placebo in participants with primary progressive multiple sclerosis (PPMS), including participants later in their disease course. This study focuses on upper limit disability progression. This study will consist of the following phases: screening, double-blind treatment, follow-up 1 (FU1), an optional open-label extension (OLE), follow-up 2 (FU2), and B-cell monitoring (BCM).
O CNS Science é uma unidade metodológica de apoio ao desenho, condução e análise de resultados de projetos de investigação clínica, integrado no CNS | Campus Neurológico
Com valências na área de metodologia da investigação clínica, neurociências, reabilitação, coordenação de projetos, gestão e análise estatística de dados e monitorização estatística de estudos, esta unidade é composta por uma equipa de profissionais de saúde e investigadores com experiência na área da investigação clínica e neurociências.
O CNS Science surge como uma unidade que aposta na colaboração e integração de diferentes áreas de conhecimento (Medicina, Neurociências, Gestão de Dados e Bioestatística) tendo como fim último a melhoria dos cuidados de saúde aos doentes.
Inserido no CNS, partilha do seu conceito de multidisciplinariedade, conciliando uma atividade clínica de qualidade com a condução de projetos de investigação e formação de profissionais de saúde, com particular foco, mas não exclusivamente, no domínio das doenças neurológicas, nomeadamente Doença de Parkinson, outras Doenças do Movimento e Doença de Alzheimer.
Qual o melhor horário de funcionamento das recepções?
O horário de funcionamento da Unidade de Internamento/ Residência Sénior é das 10h00 às 19h00, de 2ª feira a Domingo; O horário de funcionamento da Clínica Médica é das 9h00 às 21h00 de 2ª a 6ª feira e das 9h00 às 18h00 ao sábado.
Gostava de visitar as instalações, é necessário marcação?
Temos todo o prazer em mostrar as nossas instalações, mas para minimizar qualquer transtorno na rotina dos nossos residentes, horários de higienização e limpeza dos espaços, agradecemos que agende previamente.
A linha telefónica está ocupada, há outra forma de vos contactar?
Caso não pretenda aguardar em linha, por favor entre em contacto para um dos nossos e-mails disponíveis.
